Boston Scientific
Advancing science for life™

Boston Scientific – Deep Brain Stimulation

Systems Surgical Equipment Crosswalk to HCPCS Codes

The following is a list of the Vercise™ Deep Brain Stimulation (DBS) System surgical equipment, supplies and common accessories cross-walked to applicable HCPCS Level II codes. For the Medicare outpatient hospital setting, C-Codes are required for billing with applicable CPT codes, but they are not separately payable by Medicare. For most non-Medicare plans, L-Codes or Revenue Codes may be appropriate for reporting purposes. We recommend that you consult with your payer on appropriate reporting options for implantable devices and supporting accessories.

HCPCS Level II Device

UPN	Model #	Description	C-Code	L-Code
M365DB12160	DB-12160	Vercise Genus R16 Implantable Pulse Generator Kit	Part of C1820	L8687
M365DB12320	DB-1232	Vercise Genus R32 Implantable Pulse Generator Kit		
M365DB64125US0	DB-64125-US	Vercise Charging System		L8689*
M365DB14160	DB-14160	Vercise Genus P16 Implantable Pulse Generator Kit	C1767	L8688
M365DB14320	DB-1432	Vercise Genus P32 Implantable Pulse Generator Kit		
M365DB14080	DB-14080	Vercise Genus P8 Implantable Pulse Generator Kit		L8686
M365DB2202300/450	DB-2202-30/45	Vercise Cartesia™ 8-Contact Directional Lead Kit - 30cm, 45cm	C1778	L8680
M365DB220130DC0/45DC0	DB220130DC/45DC	Vercise™ Standard Lead Kit - 30cm, 45cm		
M365DB2203300/450	DB-2203-30/45	Vercise Cartesia X Directional Lead Kit – 30cm, 45cm		
M365DB2204300/450	DB-2204-30/45	Vercise Cartesia HX Directional Lead Kit - 30cm, 45cm		
M365DB557210	DB-55721A	Vercise DBS Remote Control 4 Kit	C1787	L8681
M365DB550010	DB-5500-10	Vercise DBS Remote Control Kit		
M365DB55900	DB-5590	Vercise™ DBS Controller | Patient Kit		
M365DB9218150/550	DB-9218-15/55	Vercise M8 Adapter Kit - 15cm, 55cm	C1883	L8687/L8688
M365DB9208150/550	DB-9208-15/55	Vercise Adapter S8 Kit - 15cm, 55cm		
M365NM3138550	NM-3138550	55cm 8 Contact Extension Kit		
M365DB312855/950	DB-3128-55/95	2 x 8 Contact Lead Extension Kit - 55cm, 95cm		
M365DB3216550/950	DB-3216-55/95	16-Contact Lead Extension Kit - 55cm, 95cm		

HCPCS Level II Descriptors

	HCPCS Code	Descriptor
C-Code	C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system
	C1767	Generator, neurostimulator (implantable), non-rechargeable
	C1778	Lead, neurostimulator (implantable)
	C1787	Patient programmer, neurostimulator
	C1883	Adaptor/extension, pacing lead or neurostimulator lead (implantable)
L-Code	L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
	L8689	External recharging system for battery (internal for use with implantable neurostimulator, replacement only)
	L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
	L8680	Implantable neurostimulator electrode, each
	L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
	L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension

*The provider is responsible for selecting appropriate codes. We recommend that you consult with your payer on appropriate reporting options for implantable devices and supporting accessories. The above table lists applicable device codes for Vercise™.

See important notes on the uses and limitations of this information on page 2.

Indication for Use: The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:
-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson's disease (PD) that are not adequately controlled with medication.
-Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson's disease (PD) that are not adequately controlled with medication.
-Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.
-Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability.

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:
-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson's disease (PD) that are not adequately controlled with medication.

Contraindications, warnings, precautions, side effects: The Boston Scientific Deep Brain Stimulation (DBS) Systems or any of its components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific DBS System without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately. Refer to the Instructions for Use provided with the Boston Scientific DBS Systems or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges, and modifiers for services that are rendered. Boston Scientific recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA-approved label. Information included herein is current as of November 2024 but is subject to change without notice. Rates for services are effective January 1, 2025.

Sequestration Disclaimer: Rates referenced in these guides do not reflect Sequestration; automatic reductions in federal spending that will result in a 2% across-the-board reduction to ALL Medicare rates as of January 1, 2022. (Budget Control Act of 2011)